FDA approves Camzyos for children with obstructive hypertrophic cardiomyopathy
The agency's approval marks the first drug cleared to improve functional capacity and symptoms in children with the inherited heart condition.
The U.S. Food and Drug Administration approved Camzyos (mavacamten) capsules as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.1
The drug is not new to the market. Camzyos was first approved for adults in 2022 and is now approved for both1 adult and pediatric patients with the condition, according to the FDA.
The supplied FDA record does not include additional details such as the pediatric trial name, specific dosing by age or weight, efficacy endpoint results, or the exact approval date within September 2026. Readers seeking those specifics should consult the full FDA approval letter or label update, as this record provides only the headline clearance and the drug's prior adult approval history.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.